RXRX
Price
$3.30
Change
-$0.26 (-7.30%)
Updated
Jul 13 closing price
Capitalization
1.89B
29 days until earnings call
Intraday BUY SELL Signals
SPRO
Price
$2.18
Change
+$0.08 (+3.81%)
Updated
Jul 13 closing price
Capitalization
126.23M
30 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

RXRX vs SPRO

RXRX vs SPRO Comparison Chart in %
View a ticker or compare two or three
VS
RXRX vs. SPRO commentary
Jul 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RXRX is a Buy and SPRO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 14, 2026
Stock price -- (RXRX: $3.56 vs. SPRO: $2.10)
Brand notoriety: RXRX and SPRO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RXRX: 77% vs. SPRO: 28%
Market capitalization -- RXRX: $1.75B vs. SPRO: $126.23M
RXRX [@Biotechnology] is valued at $1.75B. SPRO’s [@Biotechnology] market capitalization is $126.23M. The market cap for tickers in the [@Biotechnology] industry ranges from $121.89B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RXRX’s FA Score shows that 1 FA rating(s) are green whileSPRO’s FA Score has 1 green FA rating(s).

  • RXRX’s FA Score: 1 green, 4 red.
  • SPRO’s FA Score: 1 green, 4 red.
According to our system of comparison, both RXRX and SPRO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RXRX’s TA Score shows that 5 TA indicator(s) are bullish while SPRO’s TA Score has 5 bullish TA indicator(s).

  • RXRX’s TA Score: 5 bullish, 4 bearish.
  • SPRO’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, RXRX is a better buy in the short-term than SPRO.

Price Growth

RXRX (@Biotechnology) experienced а -6.32% price change this week, while SPRO (@Biotechnology) price change was -4.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.13%. For the same industry, the average monthly price growth was +7.30%, and the average quarterly price growth was +1806.57%.

Reported Earning Dates

RXRX is expected to report earnings on Aug 11, 2026.

SPRO is expected to report earnings on Aug 12, 2026.

Industries' Descriptions

@Biotechnology (-3.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RXRX($1.89B) has a higher market cap than SPRO($126M). SPRO YTD gains are higher at: -9.871 vs. RXRX (-12.958). SPRO has higher annual earnings (EBITDA): 14.2M vs. RXRX (-478.66M). RXRX has more cash in the bank: 654M vs. SPRO (56.1M). SPRO has less debt than RXRX: SPRO (2.47M) vs RXRX (72.4M). RXRX has higher revenues than SPRO: RXRX (65.7M) vs SPRO (54.8M).
RXRXSPRORXRX / SPRO
Capitalization1.89B126M1,500%
EBITDA-478.66M14.2M-3,371%
Gain YTD-12.958-9.871131%
P/E RatioN/A8.07-
Revenue65.7M54.8M120%
Total Cash654M56.1M1,166%
Total Debt72.4M2.47M2,926%
FUNDAMENTALS RATINGS
SPRO: Fundamental Ratings
SPRO
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
28
PRICE GROWTH RATING
1..100
79
P/E GROWTH RATING
1..100
94
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
RXRXSPRO
RSI
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
69%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
87%
Bullish Trend 4 days ago
82%
Momentum
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 4 days ago
76%
MACD
ODDS (%)
Bullish Trend 4 days ago
76%
Bearish Trend 4 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 4 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
81%
Bearish Trend 4 days ago
87%
Advances
ODDS (%)
Bullish Trend 18 days ago
83%
Bullish Trend 29 days ago
70%
Declines
ODDS (%)
Bearish Trend 21 days ago
88%
Bearish Trend 4 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
88%
Bullish Trend 4 days ago
80%
Aroon
ODDS (%)
N/A
Bearish Trend 4 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
RXRX
Daily Signal:
Gain/Loss:
SPRO
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LEISX21.950.13
+0.60%
Federated Hermes Strategic Div Gr IS
MFRJX60.490.33
+0.55%
MFS Research R4
SLADX44.820.20
+0.45%
Selected American Shares D
MDOAX12.06N/A
N/A
Morgan Stanley Developing Opportunity A
UMBHX27.89-0.28
-0.99%
Carillon Chartwell Small Cap I